SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kümpfel, T.
Right arrow Articles by Weber, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kümpfel, T.
Right arrow Articles by Weber, F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*HYDROCORTISONE
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Time of interferon-ß 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients

T. Kümpfel

Institute of Clinical Neuroimmunology, Klinikum Großhadern, Ludwig-Maximilians-Universität, Munich, Germany, tania.kuempfel{at}med.uni-muenchen.de

M. Schwan

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

Th. Pollmächer

Centre of Mental Health, Klinikum Ingolstadt, Ingoldstadt, Germany

A. Yassouridis

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

M. Uhr

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

C. Trenkwalder

Department of Clinical Neurophysiology, University of Goettingen, Germany

F. Weber

Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany

During initiation of interferon-beta (IFN-ß) therapy, many multiple sclerosis (MS) patients experience systemic side effects which may depend on the time point of IFN-ß injection. We investigated the time course of plasma hormone-, cytokine- and cytokine-receptor concentrations after the first injection of IFN-ß either at 8.00 a.m. (group A) or at 6.00 p.m. (group B) and quantified clinical side effects within the first 9 h in 16 medication free patients with relapsing-remitting MS. This investigation was repeated after 6-month IFN-ß therapy.

Plasma ACTH and cortisol concentrations followed their physiological rhythms, with lower levels in the evening compared to the morning, but raised earlier and stronger in group B after IFN-ß administration. IFN-ß injection in the evening led to a prompter increase of plasma IL-6 concentrations and temperature during the first hours and correlated to more intense clinical side effects compared to group A. Plasma IL-10 concentrations increased more in group A compared to group B, but sTNF-RI and sTNF-RII concentrations raised 7 h after IFN-ß injection only in group B. Acute effects on plasma hormone and cytokine concentrations adapted after 6-month IFN-ß treatment, while diurnal variations were still present. Baseline sTNF-RII concentrations were elevated after 6-month IFN-ß therapy only in group A.

Our results show that time point of IFN-ß injection has differential effects on acute changes of plasma hormone and cytokine concentrations and is related to systemic side effects. This may have implications on the tolerability and effectiveness of IFN-ß therapy. Multiple Sclerosis 2007; 13: 1138—1145. http://msj.sagepub.com

Key Words: time point of injection • interferon-ß • cytokine • hormones • side effects • multiple sclerosis

Multiple Sclerosis, Vol. 13, No. 9, 1138-1145 (2007)
DOI: 10.1177/1352458507078685


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement